ArticlePediatric research2012
Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant.
Article in Pediatric research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Comparative biophysical study of clinical surfactants using constrained drop surfactometry.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- The effect of temperature and breathing pattern on the surface activity of ground squirrel pulmonary surfactant.The Journal of experimental biology · 2024Article
- Thermodynamic and Structural Study of Budesonide-Exogenous Lung Surfactant System.International journal of molecular sciences · 2024Article
- Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.Bioscience reports · 2023Review
- Comparative Biophysical Study of Meibomian Lipids of Wild Type and Soat1-Null Mice: Implications to Meibomian Gland Dysfunction and Dry Eye Disease.Investigative ophthalmology & visual science · 2023Article
- Article
- Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models.Pharmaceutics · 2023Article
- Beyond the Interface: Improved Pulmonary Surfactant-Assisted Drug Delivery through Surface-Associated Structures.Pharmaceutics · 2023Article
- The concentration-dependent effect of hydrocortisone on the structure of model lung surfactant monolayer by using anRSC advances · 2022Article
- Interfacial structure of pulmonary surfactants revisited: Cholesterol and surface pressure effects.Biophysical journal · 2022Article
- Evaluating the Impact of Hydrophobic Silicon Dioxide in the Interfacial Properties of Lung Surfactant Films.Environmental science & technology · 2022Article
- An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function.Current research in toxicology · 2021Article
- In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.Pediatric research · 2017Article
- Effect of cholesterol on the molecular structure and transitions in a clinical-grade lung surfactant extract.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionCorticosteroids have been widely used in clinical medicine as a first-line therapy to modify the inflammatory response in many pulmonary and systemic diseases. Inhaled and intratracheally administered corticosteroids have a particular interest in that their use allows the clinician to circumvent systemic steroid side effects. However, it is vital that corticosteroids delivered via the lungs not interfere with surface activity of the pulmonary surfactant lining layer.
resultsWe found differential effects of cholesterol and budesonide on the biophysical properties of a cholesterol-free clinical surfactant preparation, Curosurf. At a low concentration up to 1%, both steroids play a similar role of fluidizing the surfactant film. However, when steroid concentration is increased to 10%, cholesterol induces a unique phase transition that abolishes the surface activity of the Curosurf film. By contrast, 10% budesonide simply fluidizes the film, thus having only limited effects on surface activity. DISCUSSION: Together with those of a previous study using a cholesterol-containing surfactant, our findings suggest that cholesterol-free surfactant preparations may be more advantageous than cholesterol-containing preparations as a carrier of budesonide because a larger amount of the drug may be delivered to the lungs without significantly compromising the surface activity of pulmonary surfactant.
methodsLangmuir balance was used to study the effect of cholesterol and budesonide added at different concentrations on surface activity of Curosurf. Atomic force microscopy (AFM) was used to reveal their effects on the interfacial molecular organization and lateral structure of Curosurf films.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.